Astrazeneca (AZN) Capital Leases (2012 - 2018)
Astrazeneca (AZN) recorded quarterly Capital Leases of $361.0 in Q4 2018, up 100.0% quarter-over-quarter from -$84.0 million in Q4 2012.
Astrazeneca (AZN) Capital Leases (2012 - 2018) Analysis & Trends
Astrazeneca's Capital Leases history runs 2 years deep, the most recent figure standing at $361.0 for Q4 2018.
- In Q4 2018, Capital Leases changed N/A year-over-year to $361.0; the TTM figure through Dec 2018 stood at $361.0 (changed N/A YoY), while the FY2018 annual figure was $361.0, changed N/A from the prior year.
- Capital Leases was $361.0 for Q4 2018 at Astrazeneca, up from -$84.0 million in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $361.0 in Q4 2018 to a low of $361.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Astrazeneca | 72.15 Bn | 64.21 Bn | 12.61 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 361.00 |
| Dec 31, 2012 | -84.00 Mn |